Dermatology & Venereology Department, Maggiore Hospital, University of Trieste, Trieste, Italy.
Plastic and Reconstructive Surgery Department, Section of Dermatology, Campus Biomedico University, Rome, Italy.
J Dermatolog Treat. 2022 May;33(3):1306-1311. doi: 10.1080/09546634.2021.1886232. Epub 2021 Feb 15.
Prurigo nodularis (PN) is a debilitating chronic disease characterized by intense itching and excoriated hyperkeratotic nodules distributed on the trunk and extremities, especially the extensor surfaces. The pathophysiology includes complex and not yet well-understood mechanisms involving inflammation and dysregulation of the nervous system. Currently, there are no approved therapies by the Food and Drug Administration (FDA) and the few treatment approaches for this condition are often ineffective and related to severe side effects. An emerging therapeutic option is dupilumab, a monoclonal antibody for adults and adolescents with moderate-to-severe atopic dermatitis, that inhibits interleukin-4 receptor alpha subunit (IL4-Rα) and the signaling pathways activated by interleukin (IL)-4 and IL-13. These cytokines seem to be involved in the development and perpetuation of PN and other type-2 inflammation diseases. Data on this topic are limited, but the emergent positive effects of this drug, reported in the literature and summarized in this review, suggest that it can be a safe and efficient therapy in PN.
结节性痒疹（PN）是一种使人虚弱的慢性疾病，其特征为剧烈瘙痒和角化过度的丘疹，分布于躯干和四肢，尤其是伸展表面。其病理生理学包括复杂且尚未完全了解的机制，涉及炎症和神经系统失调。目前，美国食品和药物管理局（FDA）尚未批准任何治疗方法，而针对这种情况的少数治疗方法往往无效且与严重的副作用有关。一种新兴的治疗选择是度普利尤单抗，一种用于治疗中重度特应性皮炎的成人和青少年的单克隆抗体，可抑制白细胞介素-4 受体α亚基（IL4-Rα）和白细胞介素（IL）-4 和 IL-13 激活的信号通路。这些细胞因子似乎参与了 PN 和其他 2 型炎症性疾病的发展和持续。关于这个主题的数据有限，但文献中报道的和本综述中总结的该药物的积极效果表明，它可能是 PN 的一种安全有效的治疗方法。
